Amgen, Inc. (AMGN) Stake Lifted by Intrust Bank NA

Intrust Bank NA lifted its position in Amgen, Inc. (NASDAQ:AMGN) by 4.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,799 shares of the medical research company’s stock after purchasing an additional 336 shares during the period. Intrust Bank NA’s holdings in Amgen were worth $1,454,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. First PREMIER Bank boosted its holdings in Amgen by 5.6% in the second quarter. First PREMIER Bank now owns 8,742 shares of the medical research company’s stock valued at $1,506,000 after acquiring an additional 460 shares in the last quarter. Pioneer Trust Bank N A OR boosted its holdings in Amgen by 1.6% in the second quarter. Pioneer Trust Bank N A OR now owns 18,675 shares of the medical research company’s stock valued at $3,217,000 after acquiring an additional 290 shares in the last quarter. American National Bank boosted its holdings in Amgen by 0.9% in the second quarter. American National Bank now owns 25,957 shares of the medical research company’s stock valued at $4,471,000 after acquiring an additional 231 shares in the last quarter. Xact Kapitalforvaltning AB boosted its holdings in Amgen by 1.4% in the second quarter. Xact Kapitalforvaltning AB now owns 124,819 shares of the medical research company’s stock valued at $21,498,000 after acquiring an additional 1,722 shares in the last quarter. Finally, Curbstone Financial Management Corp bought a new stake in Amgen in the second quarter valued at $226,000. Hedge funds and other institutional investors own 78.46% of the company’s stock.

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $185.04 on Friday. Amgen, Inc. has a fifty-two week low of $150.38 and a fifty-two week high of $191.10. The company has a market cap of $134,322.56, a price-to-earnings ratio of 14.71, a PEG ratio of 2.70 and a beta of 1.36. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. During the same quarter in the previous year, the business posted $3.02 EPS. The company’s quarterly revenue was down .7% on a year-over-year basis. sell-side analysts forecast that Amgen, Inc. will post 12.71 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is 41.63%.

Amgen declared that its board has initiated a stock repurchase program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Several analysts recently weighed in on AMGN shares. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 price target on the stock in a report on Friday, October 27th. Bank of America lifted their price target on shares of Amgen to $210.00 and gave the company a “buy” rating in a report on Thursday, October 5th. Barclays lifted their price target on shares of Amgen from $180.00 to $190.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Royal Bank of Canada cut their price target on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a report on Thursday, October 26th. Finally, Cann reiterated a “buy” rating and issued a $203.00 price target on shares of Amgen in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $190.15.

In other news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the completion of the transaction, the executive vice president now directly owns 56,106 shares of the company’s stock, valued at approximately $9,921,223.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,050 shares of company stock worth $1,225,765. Company insiders own 0.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.themarketsdaily.com/2018/01/14/amgen-inc-amgn-stake-lifted-by-intrust-bank-na.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply